Hoberman Alejandro, Dagan Ron, Leibovitz Eugene, Rosenblut Andres, Johnson Candice E, Huff Anne, Bandekar Rajesh, Wynne Brian
Children's Hospital of Pittsburgh, PA 15213, USA.
Pediatr Infect Dis J. 2005 Jun;24(6):525-32. doi: 10.1097/01.inf.0000164794.50281.1a.
A large dosage pediatric formulation of amoxicillin/clavulanate with an improved pharmacokinetic/pharmacodynamic profile was developed to eradicate many penicillin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae (including beta-lactamase-producing strains).
This randomized, investigator-blinded, multicenter trial examined treatment of bacterial acute otitis media (AOM) in children 6-30 months of age with amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days) versus azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days). Tympanocentesis was performed at entry for bacteriologic assessment, at the on-therapy visit (day 4-6) to determine bacterial eradication and at any time before the end-of-therapy visit (day 12-14) if the child was categorized as experiencing clinical failure. Clinical assessments were performed at the on-therapy, end-of-therapy and follow-up (day 21-25) visits.
We enrolled 730 children; AOM pathogens were isolated at baseline for 249 of the amoxicillin/clavulanate group and 245 of the azithromycin group. For children with AOM pathogens at baseline, clinical success rates at the end-of-therapy visit were 90.5% for amoxicillin/clavulanate versus 80.9% for azithromycin (P < 0.01), and those at the on-therapy and follow-up visits were 94.9% versus 88.0% and 80.3% versus 71.1%, respectively (all P < 0.05). At the on-therapy visit, pretherapy pathogens were eradicated for 94.2% of children receiving amoxicillin/clavulanate versus 70.3% of those receiving azithromycin (P < 0.001). Amoxicillin/clavulanate eradicated 96.0% of S. pneumoniae (92.0% of fully penicillin-resistant S. pneumoniae) and 89.7% of H. influenzae (85.7% [6 of 7 cases] of beta-lactamase-positive H. influenzae). Corresponding rates for azithromycin were 80.4% (54.5%) for S. pneumoniae and 49.1% (100% [1 of 1 case]) for H. influenzae (all P < 0.01 for between-drug comparisons).
Amoxicillin/clavulanate was clinically and bacteriologically more effective than azithromycin among children with bacterial AOM, including cases caused by penicillin-resistant S. pneumoniae and beta-lactamase-positive H. influenzae.
研发了一种具有改善药代动力学/药效学特征的大剂量儿科用阿莫西林/克拉维酸盐制剂,以根除许多对青霉素耐药的肺炎链球菌和流感嗜血杆菌菌株(包括产β-内酰胺酶菌株)。
这项随机、研究者设盲的多中心试验,比较了阿莫西林/克拉维酸盐(90/6.4mg/kg/日,分2次给药,共10天)与阿奇霉素(10mg/kg,第1天给药,随后5mg/kg/日,共4天)治疗6至30个月龄儿童细菌性急性中耳炎(AOM)的效果。在入组时进行鼓膜穿刺术以进行细菌学评估,在治疗期访视(第4至6天)确定细菌根除情况,若儿童被归类为临床失败,则在治疗结束访视(第12至14天)前的任何时间进行鼓膜穿刺术。在治疗期、治疗结束和随访(第21至25天)访视时进行临床评估。
我们纳入了730名儿童;阿莫西林/克拉维酸盐组249名和阿奇霉素组245名儿童在基线时分离出AOM病原体。对于基线时有AOM病原体的儿童,治疗结束访视时阿莫西林/克拉维酸盐的临床成功率为90.5%,阿奇霉素为80.9%(P<0.01),治疗期和随访访视时分别为94.9%对88.0%和80.3%对71.1%(均P<0.05)。在治疗期访视时,接受阿莫西林/克拉维酸盐治疗的儿童中94.2%的治疗前病原体被根除,接受阿奇霉素治疗的儿童中这一比例为70.3%(P<0.001)。阿莫西林/克拉维酸盐根除了96.0%的肺炎链球菌(对青霉素完全耐药的肺炎链球菌中为92.0%)和89.7%的流感嗜血杆菌(β-内酰胺酶阳性流感嗜血杆菌中85.7%[7例中的6例])。阿奇霉素对肺炎链球菌和流感嗜血杆菌的相应根除率分别为80.4%(54.5%)和49.1%(100%[1例中的1例])(药物间比较均P<0.01)。
在患有细菌性AOM的儿童中,包括由对青霉素耐药的肺炎链球菌和β-内酰胺酶阳性流感嗜血杆菌引起的病例,阿莫西林/克拉维酸盐在临床和细菌学方面比阿奇霉素更有效。